{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:42:54Z","timestamp":1795063374100,"version":"4.10.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is a chronic inflammatory cutaneous disease; it has been discovered that stimulation of the nervous system increases susceptibility to psoriasis. Although the cholinergic anti-inflammatory pathway, which is mediated by the alpha-7 nicotinic acetylcholine receptor (\u03b17nAChR), is critical for controlling multiple types of inflammation, its expression pattern and pathogenesis function in psoriatic lesioned skin tissue are unknown. We hereby analyzed the expression of \u03b17nAchR in human and mouse psoriatic skin tissue. In vivo, PNU-282987 or Methyllycaconitine, a specific agonist or antagonist of \u03b17nAchR, were administered to imiquimod (IMQ)-induced psoriatic mouse models. The macroscopic appearance and histopathological features of the psoriatic mice skin were evaluated. In addition, cell proliferation and differentiation markers were investigated. The level of pro-inflammatory cytokines released from the lesioned skin, as well as the activation of the relevant signaling pathways, were measured. Our findings indicated that psoriatic lesional skin expressed an increased level of \u03b17nAChR, with its tissue distribution being primarily in skin keratinocytes and macrophages. In an IMQ-induced murine psoriasis model, \u03b17nAChR agonist PNU-282987 treatment alleviated psoriasis-like inflammation by down-regulating the expression of multiple types of pro-inflammatory mediators and normalized keratinocyte proliferation and differentiation, whereas \u03b17nAChR antagonist treatment exacerbated its effect. Mechanically, we observed that activation of the \u03b17nAChR inhibited the activation of the STAT3 and NF-\u03baB signaling pathways in in vitro cultured HaCaT cells induced by Th17-related cytokine IL-6\/IL-22 or Th1-related cytokine TNF-\u03b1. Taken together, these findings demonstrate that attenuation of psoriatic inflammation via the cholinergic anti-inflammatory pathway is dependent on \u03b17nAChR activation.<\/jats:p>","DOI":"10.1038\/s41420-022-00943-4","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:04:43Z","timestamp":1648613083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Alpha-7 nicotinic acetylcholine receptor agonist alleviates psoriasis-like inflammation through inhibition of the STAT3 and NF-\u03baB signaling pathway"],"prefix":"10.1038","volume":"8","author":[{"given":"Yiwen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-4716","authenticated-orcid":false,"given":"Junaid","family":"Wazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2868-5112","authenticated-orcid":false,"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"943_CR1","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020;369:m1590.","journal-title":"BMJ"},{"key":"943_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645\u201353.","journal-title":"J Allergy Clin Immunol."},{"key":"943_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12016-016-8535-x","volume":"50","author":"Y Deng","year":"2016","unstructured":"Deng Y, Chang C, Lu Q. The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol. 2016;50:377\u201389.","journal-title":"Clin Rev Allergy Immunol."},{"key":"943_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.26444\/aaem\/112107","volume":"27","author":"M Roszkiewicz","year":"2020","unstructured":"Roszkiewicz M, Dopytalska K, Szymanska E, Jakimiuk A, Walecka I. Environmental risk factors and epigenetic alternations in psoriasis. Ann Agric Environ Med. 2020;27:335\u201342.","journal-title":"Ann Agric Environ Med"},{"key":"943_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000106419","volume":"35","author":"E Dika","year":"2007","unstructured":"Dika E, Bardazzi F, Balestri R, Maibach HI. Environmental factors and psoriasis. Curr Probl Dermatol. 2007;35:118\u201335.","journal-title":"Curr Probl Dermatol"},{"key":"943_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00281-018-0675-z","volume":"40","author":"JE Choi","year":"2018","unstructured":"Choi JE, Di Nardo A. Skin neurogenic inflammation. Semin Immunopathol. 2018;40:249\u201359.","journal-title":"Semin Immunopathol."},{"key":"943_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature01339","volume":"421","author":"H Wang","year":"2003","unstructured":"Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421:384\u20138.","journal-title":"Nature."},{"key":"943_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.redox.2017.11.013","volume":"15","author":"DJ Li","year":"2018","unstructured":"Li DJ, Fu H, Tong J, Li YH, Qu LF, Wang P, et al. Cholinergic anti-inflammatory pathway inhibits neointimal hyperplasia by suppressing inflammation and oxidative stress. Redox Biol. 2018;15:22\u201333.","journal-title":"Redox Biol."},{"key":"943_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jneuroim.2010.09.008","volume":"230","author":"R Benfante","year":"2011","unstructured":"Benfante R, Antonini RA, De Pizzol M, Gotti C, Clementi F, Locati M, et al. Expression of the \u03b17 nAChR subunit duplicate form (CHRFAM7A) is down-regulated in the monocytic cell line THP-1 on treatment with LPS. J Neuroimmunol. 2011;230:74\u201384.","journal-title":"J Neuroimmunol."},{"key":"943_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/med.21291","volume":"34","author":"L Jin","year":"2014","unstructured":"Jin L, Wang G. Keratin 17: A critical player in the pathogenesis of psoriasis. Med Res Rev. 2014;34:438\u201354.","journal-title":"Med Res Rev."},{"key":"943_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","volume":"11","author":"S Sano","year":"2005","unstructured":"Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11:43\u201349.","journal-title":"Nat Med"},{"key":"943_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7888\/juoeh.32.317","volume":"32","author":"Y Tokura","year":"2010","unstructured":"Tokura Y, Mori T, Hino R. Psoriasis and other th17-mediated skin diseases. J UOEH. 2010;32:317\u201328.","journal-title":"J UOEH"},{"key":"943_CR13","doi-asserted-by":"crossref","unstructured":"Benhadou F, Mintoff D, Del Marmol V. Psoriasis: keratinocytes or immune cells\u2014which is the trigger? Dermatology. 2019;235:91\u2013100.","DOI":"10.1159\/000495291"},{"key":"943_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/17425255.2019.1681969","volume":"15","author":"A Campanati","year":"2019","unstructured":"Campanati A, Paolinelli M, Diotallevi F, Martina E, Molinelli E, Offidani A. Pharmacodynamics of TNF alpha inhibitors for the treatment of psoriasis. Expert Opin Drug Metab Toxicol. 2019;15:913\u201325.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"943_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2016.12.014","volume":"117","author":"A Kanashiro","year":"2017","unstructured":"Kanashiro A, Sonego F, Ferreira RG, Castanheira FV, Leite CA, Borges VF, et al. Therapeutic potential and limitations of cholinergic anti-inflammatory pathway in sepsis. Pharm Res. 2017;117:1\u20138.","journal-title":"Pharm Res"},{"key":"943_CR16","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/jcp.29101","volume":"235","author":"GL Antunes","year":"2020","unstructured":"Antunes GL, Silveira JS, Kaiber DB, Luft C, da Costa MS, Marques EP, et al. Cholinergic anti-inflammatory pathway confers airway protection against oxidative damage and attenuates inflammation in an allergic asthma model. J Cell Physiol. 2020;235:1838\u201349.","journal-title":"J Cell Physiol."},{"key":"943_CR17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00011-012-0513-z","volume":"61","author":"N Zoheir","year":"2012","unstructured":"Zoheir N, Lappin DF, Nile CJ. Acetylcholine and the alpha 7 nicotinic receptor: a potential therapeutic target for the treatment of periodontal disease? Inflamm Res. 2012;61:915\u201326.","journal-title":"Inflamm Res"},{"key":"943_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00418-011-0798-y","volume":"135","author":"Y-Y Fan","year":"2011","unstructured":"Fan Y-Y, Yu T-S, Wang T, Liu W-W, Zhao R, Zhang S-T, et al. Nicotinic acetylcholine receptor \u03b17 subunit is time-dependently expressed in distinct cell types during skin wound healing in mice. Histochemistry Cell Biol. 2011;135:375\u201387.","journal-title":"Histochemistry Cell Biol."},{"key":"943_CR19","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.4049\/jimmunol.181.7.4733","volume":"181","author":"I Kryczek","year":"2008","unstructured":"Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, et al. Induction of il-17+ t cell trafficking and development by IFN-gamma: Mechanism and pathological relevance in psoriasis. J Immunol. 2008;181:4733\u201341.","journal-title":"J Immunol."},{"key":"943_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2013.01.057","volume":"132","author":"J Esparza-Gordillo","year":"2013","unstructured":"Esparza-Gordillo J, Schaarschmidt H, Liang L, Cookson W, Bauerfeind A, Lee-Kirsch M-A, et al. A functional il-6 receptor (il6r) variant is a risk factor for persistent atopic dermatitis. J allergy Clin Immunol. 2013;132:371\u20137.","journal-title":"J allergy Clin Immunol."},{"key":"943_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1346-8138.14139","volume":"45","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45:264\u201372.","journal-title":"J Dermatol."},{"key":"943_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40261-017-0596-y","volume":"38","author":"A Azevedo","year":"2018","unstructured":"Azevedo A, Torres T. Tofacitinib: A new oral therapy for psoriasis. Clin Drug Investig. 2018;38:101\u201312.","journal-title":"Clin Drug Investig."},{"key":"943_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/exd.12585","volume":"24","author":"V Orecchia","year":"2015","unstructured":"Orecchia V, Regis G, Tassone B, Valenti C, Avalle L, Saoncella S, et al. Constitutive stat3 activation in epidermal keratinocytes enhances cell clonogenicity and favours spontaneous immortalization by opposing differentiation and senescence checkpoints. Exp Dermatol. 2015;24:29\u201334.","journal-title":"Exp Dermatol"},{"key":"943_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2015.09.045","volume":"74","author":"R Shreberk-Hassidim","year":"2016","unstructured":"Shreberk-Hassidim R, Ramot Y, Gilula Z, Zlotogorski A. A systematic review of pulse steroid therapy for alopecia areata. J Am Acad Dermatol. 2016;74:372\u20134. e371-375","journal-title":"J Am Acad Dermatol."},{"key":"943_CR25","doi-asserted-by":"publisher","first-page":"173239","DOI":"10.1016\/j.ejphar.2020.173239","volume":"882","author":"NM Pinheiro","year":"2020","unstructured":"Pinheiro NM, Miranda C, Santana FR, Bittencourt-Mernak M, Arantes-Costa FM, Olivo C, et al. Effects of VAChT reduction and alpha7nAChR stimulation by PNU-282987 in lung inflammation in a model of chronic allergic airway inflammation. Eur J Pharmacol. 2020;882:173239.","journal-title":"Eur J Pharmacol."},{"key":"943_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/jid.2015.82","volume":"135","author":"S Xie","year":"2015","unstructured":"Xie S, Su Z, Zhang B, Ge J, Song S, Sun G, et al. Sirt1 activation ameliorates Aldara-induced psoriasiform phenotype and histology in mice. J Invest Dermatol. 2015;135:1915\u20138.","journal-title":"J Invest Dermatol"},{"key":"943_CR27","doi-asserted-by":"publisher","first-page":"212570","DOI":"10.7573\/dic.212570","volume":"8","author":"AC Foulkes","year":"2019","unstructured":"Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.","journal-title":"Drugs Context"},{"key":"943_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/14712598.2018.1445223","volume":"18","author":"M Megna","year":"2018","unstructured":"Megna M, Balato A, Raimondo A, Balato N. Guselkumab for the treatment of psoriasis. Expert Opin Biol Th. 2018;18:459\u201368.","journal-title":"Expert Opin Biol Th"},{"key":"943_CR29","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3389\/fimmu.2019.03096","volume":"10","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Boehncke WH, Ghoreschi K, Gori T, Kaya Z, Thaci D, et al. Il-17a in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096.","journal-title":"Front Immunol."},{"key":"943_CR30","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke WH. The il-17 family of cytokines in psoriasis: Il-17a and beyond. Front Immunol. 2018;9:1682.","journal-title":"Front Immunol."},{"key":"943_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.311","volume":"41","author":"RP Nair","year":"2009","unstructured":"Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with il-23 and NF-kappaB pathways. Nat Genet. 2009;41:199\u2013204.","journal-title":"Nat Genet."},{"key":"943_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8652","volume":"6","author":"S Yan","year":"2015","unstructured":"Yan S, Xu Z, Lou F, Zhang L, Ke F, Bai J, et al. NF-kappaB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis. Nat Commun. 2015;6:7652.","journal-title":"Nat Commun."},{"key":"943_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","volume":"96","author":"P Ettehadi","year":"1994","unstructured":"Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146\u201351.","journal-title":"Clin Exp Immunol."},{"key":"943_CR34","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/eji.1830270718","volume":"27","author":"S Kondo","year":"1997","unstructured":"Kondo S, Sauder DN. Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-alpha-induced skin inflammation. Eur J Immunol. 1997;27:1713\u20138.","journal-title":"Eur J Immunol."},{"key":"943_CR35","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"L van der Fits","year":"2009","unstructured":"van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the il-23\/il-17 axis. J. Immunol. 2009;182:5836\u201345.","journal-title":"J. Immunol."},{"key":"943_CR36","unstructured":"Prophet EB, Mills B, Arrington JB, Sobin LH. Laboratory methods in histotechnology. USA: American Registry of Pathology; 1992."}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-00943-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-00943-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-00943-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:19:50Z","timestamp":1669303190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-00943-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1038\/s41420-022-00943-4","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors state no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}